Growth hormone and aging.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms and observational human syndromes without systematic search criteria or pooled data.
PubMed 33001358 · doi:10.1007/s11154-020-09593-2
What was done
This narrative review synthesized evidence regarding the effects of growth hormone (GH) on growth, body size, metabolism, and aging, detailing evolutionarily conserved signaling pathways (insulin/IGF-1 and mTOR) and comparing findings from mammalian models to human syndromes of GH deficiency and GH resistance.
What was found
The abstract reports no quantitative values or statistical effect sizes. It qualitatively reports that lack of GH results in reduced body size, delayed maturation, and significant lifespan extension in mammalian models. In humans, syndromes of GH deficiency or resistance do not extend overall longevity, but they are associated with reduced risk of age-related chronic diseases and improved healthspan metrics.
Why it matters
The review clarifies an evolutionary trade-off between anabolic growth signaling and lifespan, distinguishing the robust longevity extension seen in GH-deficient animal models from the human phenotype, where GH reduction improves chronic disease profiles without extending overall survival.
Limits
As a narrative review, it lacks systematic search methodology, meta-analytic pooling, and risk of bias assessment. The abstract presents no quantitative data. Human evidence is largely drawn from rare genetic syndromes, which may not directly generalize to normal physiological variations in GH secretion in the wider population.
Cited by
- supports Elevating growth hormone and IGF-1 levels decreases lifespan in animals, and differences in IGF-1 dosing explain why larger dogs have shorter lifespans than small dogs.